Online inquiry

IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ842MR)

This product GTTS-WQ842MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD276 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001024736.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 80381
UniProt ID Q5ZPR3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ842MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11879MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MLN-0264
GTTS-WQ3211MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ARGX-110
GTTS-WQ6165MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CP-751871
GTTS-WQ15276MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Theraloc
GTTS-WQ8220MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HLX-06
GTTS-WQ10899MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MABp1
GTTS-WQ3997MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BGB-A317
GTTS-WQ11932MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MLN2045
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW